Follow
Patrick Bhola
Patrick Bhola
Instructor, Dana Farber Cancer Institute
Verified email at dfci.harvard.edu
Title
Cited by
Cited by
Year
Mitochondria—judges and executioners of cell death sentences
PD Bhola, A Letai
Molecular cell 61 (5), 695-704, 2016
3392016
Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics
KA Sarosiek, C Fraser, N Muthalagu, PD Bhola, W Chang, SK McBrayer, ...
Cancer cell 31 (1), 142-156, 2017
2382017
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
D Lagares, A Santos, PE Grasberger, F Liu, CK Probst, RA Rahimi, ...
Science translational medicine 9 (420), eaal3765, 2017
1912017
Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations
A Letai, P Bhola, AL Welm
Cancer cell 40 (1), 26-35, 2022
1202022
Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control
A Mahdavi, RE Davey, P Bhola, T Yin, PW Zandstra
PLoS Computational Biology 3 (7), e130, 2007
872007
MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia
FC Brown, E Still, RP Koche, CY Yim, S Takao, P Cifani, C Reed, ...
Cancer discovery 8 (4), 478-497, 2018
652018
Spatial and temporal dynamics of mitochondrial membrane permeability waves during apoptosis
PD Bhola, AL Mattheyses, SM Simon
Biophysical journal 97 (8), 2222-2231, 2009
552009
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors
PD Bhola, E Ahmed, JL Guerriero, E Sicinska, E Su, E Lavrova, J Ni, ...
Science Signaling 13 (636), eaay1451, 2020
482020
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia
PD Bhola, BG Mar, RC Lindsley, JA Ryan, LJ Hogdal, TT Vo, ...
The Journal of clinical investigation 126 (10), 3827-3836, 2016
452016
Determinism and divergence of apoptosis susceptibility in mammalian cells
PD Bhola, SM Simon
Journal of cell science 122 (23), 4296-4302, 2009
422009
Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer
EH Stover, MB Baco, O Cohen, YY Li, EL Christie, M Bagul, A Goodale, ...
Molecular Cancer Research 17 (11), 2281-2293, 2019
342019
Synergistic interactions with PI3K inhibition that induce apoptosis
Y Zwang, O Jonas, C Chen, ML Rinne, JG Doench, F Piccioni, L Tan, ...
elife 6, e24523, 2017
322017
Identification of novel therapeutic targets for fibrolamellar carcinoma using patient-derived xenografts and direct-from-patient screening
G Lalazar, D Requena, L Ramos-Espiritu, D Ng, PD Bhola, YP De Jong, ...
Cancer discovery 11 (10), 2544-2563, 2021
282021
Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
DS Potter, R Du, P Bhola, R Bueno, A Letai
Cell death & disease 12 (8), 1-12, 2021
202021
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics
VW Daniels, JJ Zoeller, N Van Gastel, KE McQueeney, S Parvin, ...
Science signaling 14 (686), eabc7405, 2021
132021
High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
A Letai, P Bhola, J Ryan
US Patent 10,761,086, 2020
102020
Compositions and methods for assessing toxicity using dynamic bh3 profiling
A Letai, P Bhola, R Jeremy
82016
Preclinical modeling of leiomyosarcoma identifies susceptibility to transcriptional CDK inhibitors through antagonism of E2F-driven oncogenic gene expression
ML Hemming, P Bhola, MA Loycano, JA Anderson, ML Taddei, LA Doyle, ...
Clinical Cancer Research 28 (11), 2397-2408, 2022
62022
Live cell imaging dynamic bh3 profiling
A Letai, P Bhola, R German
US Patent App. 17/433,970, 2022
32022
Compositions and methods for assessing toxicity using dynamic bh3 profiling
A Letai, P Bhola, J Ryan
US Patent App. 17/186,344, 2021
32021
The system can't perform the operation now. Try again later.
Articles 1–20